Identification
- Name
- Serine
- Accession Number
- DB00133
- Description
A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from glycine or threonine. It is involved in the biosynthesis of purines; pyrimidines; and other amino acids.
- Type
- Small Molecule
- Groups
- Investigational, Nutraceutical
- Structure
Structure for Serine (DB00133)
- Weight
- Average: 105.0926
Monoisotopic: 105.042593095 - Chemical Formula
- C3H7NO3
- Synonyms
- (S)-2-Amino-3-hydroxypropanoic acid
- (S)-Serine
- alpha-Amino-beta-hydroxypropionic acid
- beta-Hydroxyalanine
- L-Serine
- Ser
- Serina
- Serine
- Serinum
Pharmacology
- Indication
Used as a natural moisturizing agent in some cosmetics and skin care products.
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
Serine is classified as a nutritionally non-essential amino acid. Serine is critical for the production of the body's proteins, enzymes and muscle tissue. Serine is needed for the proper metabolism of fats and fatty acids. It also helps in the production of antibodies. Serine is used as a natural moisturizing agent in some cosmetics and skin care products. The main source of essential amino acids is from the diet, non-essential amino acids are normally synthesize by humans and other mammals from common intermediates.
- Mechanism of action
L-Serine plays a role in cell growth and development (cellular proliferation). The conversion of L-serine to glycine by serine hydroxymethyltransferase results in the formation of the one-carbon units necessary for the synthesis of the purine bases, adenine and guanine. These bases when linked to the phosphate ester of pentose sugars are essential components of DNA and RNA and the end products of energy producing metabolic pathways, ATP and GTP. In addition, L-serine conversion to glycine via this same enzyme provides the one-carbon units necessary for production of the pyrimidine nucleotide, deoxythymidine monophosphate, also an essential component of DNA.
Target Actions Organism UCystathionine beta-synthase Not Available Humans UL-serine dehydratase/L-threonine deaminase Not Available Humans USerine racemase Not Available Humans USerine palmitoyltransferase 2 Not Available Humans USerine palmitoyltransferase 1 Not Available Humans USerine--tRNA ligase, cytoplasmic Not Available Humans USerine--pyruvate aminotransferase Not Available Humans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Serine (125 mg) + Alanine (520 mg) + Arginine (290 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + Isoleucine (150 mg) + L-Lysine (145 mg) + Leucine (182.5 mg) + Magnesium chloride (25.5 mg) + Methionine (100 mg) + Phenylalanine (140 mg) + Proline (170 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Tyrosine (10 mg) + Valine (145 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2015-08-05 Canada 
2.5%travasol Amino Acid InJ.W.eleC.W.25%dex Serine (125 mg) + Alanine (520 mg) + Arginine (290 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + Isoleucine (150 mg) + L-Lysine (145 mg) + Leucine (182.5 mg) + Magnesium chloride (25.5 mg) + Methionine (100 mg) + Phenylalanine (140 mg) + Proline (170 mg) + Sodium acetate (170 mg) + Sodium chloride (29.3 mg) + Threonine (105 mg) + Tryptophan (45 mg) + Tyrosine (10 mg) + Valine (145 mg) Liquid Intravenous Clintec Nutrition Company 1996-07-30 1998-08-13 Canada 2.75% Travas. Amino Acid InJ.W.elecw.25%dex Serine (137.5 mg) + Alanine (570 mg) + Arginine (316 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + Isoleucine (165 mg) + L-Lysine (159.5 mg) + Leucine (201 mg) + Magnesium chloride (51 mg) + Methionine (110 mg) + Phenylalanine (154 mg) + Proline (187 mg) + Sodium acetate (215.5 mg) + Sodium chloride (112 mg) + Threonine (115.5 mg) + Tryptophan (49.5 mg) + Tyrosine (11 mg) + Valine (159.5 mg) Liquid Intravenous Clintec Nutrition Company 1996-07-30 1998-08-13 Canada 2.75%travasol Amino Acid InJ.W.eleC.W.5%dex. Serine (137.5 mg) + Alanine (570 mg) + Arginine (316 mg) + Dextrose, unspecified form (5 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + Isoleucine (165 mg) + L-Lysine (159.5 mg) + Leucine (201 mg) + Magnesium chloride (51 mg) + Methionine (110 mg) + Phenylalanine (154 mg) + Proline (187 mg) + Sodium acetate (215 mg) + Sodium chloride (112 mg) + Threonine (115.5 mg) + Tryptophan (49.5 mg) + Tyrosine (11 mg) + Valine (159.5 mg) Liquid Intravenous Clintec Nutrition Company 1996-12-31 1999-08-10 Canada 20% Prosol Serine (1.02 g) + Alanine (2.76 g) + Arginine (1.96 g) + Aspartic acid (0.6 g) + D-Methionine (0.76 g) + Glutamic acid (1.02 g) + Glycine (2.06 g) + Histidine (1.18 g) + Isoleucine (1.08 g) + L-Lysine (1.35 g) + Leucine (1.08 g) + Methionine (0.76 g) + Phenylalanine (1 g) + Proline (1.34 g) + Threonine (0.98 g) + Tryptophan (0.32 g) + Tyrosine (0.05 g) + Valine (1.44 g) Liquid Intravenous Baxter Laboratories 1996-10-09 Not applicable Canada 4.25% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Serine (212.5 mg) + Alanine (880 mg) + Arginine (489 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (261 mg) + Glycine (438 mg) + Histidine (204 mg) + Isoleucine (255 mg) + L-Lysine hydrochloride (246.5 mg) + Leucine (310 mg) + Magnesium chloride (51 mg) + Methionine (170 mg) + Phenylalanine (238 mg) + Proline (289 mg) + Sodium acetate (297 mg) + Sodium chloride (77 mg) + Threonine (178.5 mg) + Tryptophan (76.5 mg) + Tyrosine (17 mg) + Valine (246.5 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2015-08-05 Canada 4.25% Travasol Amino Acid Injection With Electrolytes In 20% Dextrose Serine (212.5 mg) + Alanine (880 mg) + Arginine (489 mg) + Dextrose, unspecified form (20 g) + Dipotassium phosphate (261 mg) + Glycine (438 mg) + Histidine (204 mg) + Isoleucine (255 mg) + L-Lysine hydrochloride (246.5 mg) + Leucine (310 mg) + Magnesium chloride (51 mg) + Methionine (170 mg) + Phenylalanine (238 mg) + Proline (289 mg) + Sodium acetate (297 mg) + Sodium chloride (77 mg) + Threonine (178.5 mg) + Tryptophan (76.5 mg) + Tyrosine (17 mg) + Valine (246.5 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2007-08-02 Canada 4.25% Travasol Amino Acid Injection With Electrolytes In 25% Dextrose Serine (212.5 mg) + Alanine (880 mg) + Arginine (489 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (438 mg) + Histidine (204 mg) + Isoleucine (255 mg) + L-Lysine hydrochloride (246.5 mg) + Leucine (310 mg) + Magnesium chloride (51 mg) + Methionine (170 mg) + Phenylalanine (238 mg) + Proline (289 mg) + Sodium acetate (297 mg) + Sodium chloride (77 mg) + Threonine (178.5 mg) + Tryptophan (76.5 mg) + Tyrosine (17 mg) + Valine (246.5 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2015-08-05 Canada 4.25% Travasol Amino Acid Injection Without Electrlytes In 10% Dextrose Serine (212.5 mg) + Alanine (880 mg) + Arginine (489 mg) + Dextrose, unspecified form (10 g) + Glycine (438 mg) + Histidine (204 mg) + Isoleucine (255 mg) + L-Lysine hydrochloride (246.5 mg) + Leucine (310 mg) + Methionine (170 mg) + Phenylalanine (238 mg) + Proline (289 mg) + Threonine (178.5 mg) + Tryptophan (76.5 mg) + Tyrosine (17 mg) + Valine (246.5 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2015-08-05 Canada 4.25% Travasol Amino Acid Injection Without Electrolytes In 20% Dextrose Serine (212.5 mg) + Alanine (880 mg) + Arginine (489 mg) + Dextrose, unspecified form (20 g) + Glycine (438 mg) + Histidine (204 mg) + Isoleucine (255 mg) + L-Lysine hydrochloride (246.5 mg) + Leucine (310 mg) + Methionine (170 mg) + Phenylalanine (238 mg) + Proline (289 mg) + Threonine (178.5 mg) + Tryptophan (76.5 mg) + Tyrosine (17 mg) + Valine (246.5 mg) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2007-08-02 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Clinimix Serine (1.38 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (100.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Lysine (2.00 g/1L) + Leucine (2.01 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US 
Clinimix Serine (4.25 g/2L) + Alanine (17.60 g/2L) + Arginine (9.78 g/2L) + Calcium chloride dihydrate (0.66 g/2L) + D-glucose monohydrate (300.00 g/2L) + Dipotassium phosphate (5.22 g/2L) + Glycine (8.76 g/2L) + Histidine (4.08 g/2L) + Isoleucine (5.10 g/2L) + L-Lysine (4.93 g/2L) + Leucine (6.20 g/2L) + Magnesium chloride hexahydrate (1.02 g/2L) + Methionine (3.40 g/2L) + Phenylalanine (4.76 g/2L) + Proline (5.78 g/2L) + Sodium acetate trihydrate (5.94 g/2L) + Sodium chloride (1.54 g/2L) + Threonine (3.57 g/2L) + Tryptophan (1.53 g/2L) + Tyrosine (0.34 g/2L) + Valine (4.93 g/2L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US Clinimix Serine (1.38 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (75.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + L-Lysine (2.00 g/1L) + Leucine (2.01 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Threonine (1.16 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US Primene Serine (1 g/250mL) + Alanine (2 g/250mL) + Arginine (2.1 g/250mL) + Aspartic acid (1.5 g/250mL) + Cysteine (0.47 g/250mL) + Glutamic acid (2.5 g/250mL) + Glycine (1 g/250mL) + Histidine (0.95 g/250mL) + Isoleucine (1.675 g/250mL) + L-Lysine (2.75 g/250mL) + Leucine (2.5 g/250mL) + Methionine (0.6 g/250mL) + Ornithine hydrochloride (0.8 g/250mL) + Phenylalanine (1.05 g/250mL) + Proline (0.75 g/250mL) + Taurine (0.15 g/250mL) + Threonine (0.9 g/250mL) + Tryptophan (0.5 g/250mL) + Tyrosine (0.11 g/250mL) + Valine (1.9 g/250mL) Injection, solution Intravenous Baxter Healthcare Corporation 2017-11-22 2019-05-31 US Synthamin Serine (5 g/1000mL) + Alanine (20.70 g/1000mL) + Arginine (11.50 g/1000mL) + Glycine (10.30 g/1000mL) + Histidine (4.80 g/1000mL) + Isoleucine (6 g/1000mL) + L-Lysine (5.80 g/1000mL) + Leucine (7.30 g/1000mL) + Methionine (4 g/1000mL) + Phenylalanine (5.60 g/1000mL) + Proline (6.80 g/1000mL) + Threonine (4.20 g/1000mL) + Tryptophan (1.80 g/1000mL) + Tyrosine (400 mg/1000mL) + Valine (5.80 g/1000mL) Injection, solution Intravenous Baxter Healthcare Corporation 2017-11-03 2020-06-30 US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as serine and derivatives. These are compounds containing serine or a derivative thereof resulting from reaction of serine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Serine and derivatives
- Alternative Parents
- L-alpha-amino acids / Beta hydroxy acids and derivatives / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Primary alcohols / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives show 1 more
- Substituents
- Alcohol / Aliphatic acyclic compound / Alpha-amino acid / Amine / Amino acid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Hydrocarbon derivative / Hydroxy acid show 12 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- proteinogenic amino acid, L-alpha-amino acid, serine, serine family amino acid (CHEBI:17115) / Common amino acids (C00065)
Chemical Identifiers
- UNII
- 452VLY9402
- CAS number
- 56-45-1
- InChI Key
- MTCFGRXMJLQNBG-REOHCLBHSA-N
- InChI
- InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m0/s1
- IUPAC Name
- (2S)-2-amino-3-hydroxypropanoic acid
- SMILES
- N[[email protected]@H](CO)C(O)=O
References
- Synthesis Reference
Kenichi Ishiwata, Nobuyoshi Makiguichi, Hideki Kawashima, Tadashi Suzuki, Masami Imadegawa, "Method of producing L-serine." U.S. Patent US4782021, issued August, 1973.
US4782021- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000187
- KEGG Drug
- D00016
- KEGG Compound
- C00065
- PubChem Compound
- 5951
- PubChem Substance
- 46506450
- ChemSpider
- 5736
- BindingDB
- 50357212
- 9671
- ChEBI
- 33384
- ChEMBL
- CHEMBL11298
- ZINC
- ZINC000000895034
- PharmGKB
- PA451330
- Guide to Pharmacology
- GtP Drug Page
- PDBe Ligand
- SER
- Wikipedia
- Serine
- MSDS
- Download (72.9 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Terminated Supportive Care Cancer-related Malnutrition 1 4 Terminated Supportive Care Illness, Critical 1 4 Terminated Supportive Care Parenteral Nutrition (No Primary Condition Studied) 1 4 Withdrawn Supportive Care Malnutrition 1 3 Completed Treatment General Surgery / Parenteral Feeding 1 3 Completed Treatment General Surgery / Parenteral Nutrition 1 3 Completed Treatment Illness, Critical 1 3 Completed Treatment Infant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants / Sepsis 1 3 Completed Treatment Parents 2 3 Terminated Treatment Malignant Neoplasm of Pancreas 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Spectrum Pharmaceuticals
- Dosage Forms
Form Route Strength Liquid Intravenous Injection, solution Intravenous 2.5 g/500mL Solution Intravenous 2.453 g Solution, concentrate Intravenous 5 g Solution Intravenous 10.4 g/L Injection, solution Intravenous Solution Intravenous 5 g Solution Intravenous 4.15 g Solution Intravenous 1.566 g Solution Intraperitoneal 951 mg/L Solution Intravenous 0.69 % Solution Intravenous 0.59 % Injection Intravenous Solution Intravenous 1.03 g Injection, emulsion Intravenous Injection Intravenous 110 g Injection Intravenous 165 g Injection Intravenous 220 g Injection Intravenous 275 g Injection Intravenous 107 g Injection Intravenous 143 g Injection Intravenous 178 g Injection, solution Intravenous 600 mg/200mL Solution 16 g/L Injection, solution, concentrate Intravenous Emulsion Intravenous 1.83 g Injection Intravenous 1.03 g Injection, emulsion Intravenous 1.6 g/100mL Injection, emulsion; injection, solution Intravenous 3.2 g/100mL Emulsion Intravenous 20 mg Emulsion Intravenous 16 g Liquid Hemodialysis Solution Intraperitoneal 510 mg/l Injection, emulsion Intravenous 1.6 g Injection Intravenous 2.27 g/l Injection Intravenous 4.12 g/l Emulsion Intravenous 4 g Solution Intravenous 7.14 g Solution Intravenous 9.52 g Solution Intravenous 11.9 g Emulsion Intravenous 6.41 g Emulsion Intravenous 9.61 g Emulsion Intravenous 12.82 g Solution Intravenous 8.24 g Solution Intravenous 12.36 g Solution Intravenous 16.48 g Emulsion Intravenous Emulsion Intravenous 3 g Injection, solution Intravenous 0.69 % Injection, solution Intravenous 0.59 % Injection, solution Intravenous 0.9 % Injection, solution Intravenous 0.49 % Injection, solution Intravenous 0.76 % Solution Intravenous Solution 3.2 g/100mL Solution 1.6 g/100mL Injection Intravenous 0.67 g/100ml Solution Parenteral 3 g/100ml Emulsion Parenteral 50 g Injection, solution Intravenous 0.76 g/100mL Solution Intravenous 434 mg Solution Intravenous 594 mg Solution Intravenous 12 g/L Solution Intravenous 16 g/L Solution Intravenous 5.1 g/16g N - Prices
Unit description Cost Unit L-serine powder 3.85USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 228 dec °C PhysProp water solubility 4.25E+005 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP -3.07 HANSCH,C ET AL. (1995) pKa 2.21 (at 25 °C) KORTUM,G ET AL (1961) - Predicted Properties
Property Value Source Water Solubility 480.0 mg/mL ALOGPS logP -3.4 ALOGPS logP -3.9 ChemAxon logS 0.66 ALOGPS pKa (Strongest Acidic) 2.03 ChemAxon pKa (Strongest Basic) 8.93 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 83.55 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 22.04 m3·mol-1 ChemAxon Polarizability 9.39 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9407 Blood Brain Barrier - 0.6529 Caco-2 permeable - 0.7839 P-glycoprotein substrate Non-substrate 0.7693 P-glycoprotein inhibitor I Non-inhibitor 0.9862 P-glycoprotein inhibitor II Non-inhibitor 0.9877 Renal organic cation transporter Non-inhibitor 0.9436 CYP450 2C9 substrate Non-substrate 0.8673 CYP450 2D6 substrate Non-substrate 0.846 CYP450 3A4 substrate Non-substrate 0.8389 CYP450 1A2 substrate Non-inhibitor 0.9087 CYP450 2C9 inhibitor Non-inhibitor 0.9512 CYP450 2D6 inhibitor Non-inhibitor 0.9349 CYP450 2C19 inhibitor Non-inhibitor 0.945 CYP450 3A4 inhibitor Non-inhibitor 0.908 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9914 Ames test Non AMES toxic 0.9088 Carcinogenicity Non-carcinogens 0.82 Biodegradation Ready biodegradable 0.9489 Rat acute toxicity 1.2700 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9923 hERG inhibition (predictor II) Non-inhibitor 0.9811
Spectra
- Mass Spec (NIST)
- Download (8.77 KB)
- Spectra
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Ubiquitin protein ligase binding
- Specific Function
- Hydro-lyase catalyzing the first step of the transsulfuration pathway, where the hydroxyl group of L-serine is displaced by L-homocysteine in a beta-replacement reaction to form L-cystathionine, th...
- Gene Name
- CBS
- Uniprot ID
- P35520
- Uniprot Name
- Cystathionine beta-synthase
- Molecular Weight
- 60586.05 Da
References
- Sen S, Banerjee R: A pathogenic linked mutation in the catalytic core of human cystathionine beta-synthase disrupts allosteric regulation and allows kinetic characterization of a full-length dimer. Biochemistry. 2007 Apr 3;46(13):4110-6. Epub 2007 Mar 13. [PubMed:17352495]
- Qu K, Lee SW, Bian JS, Low CM, Wong PT: Hydrogen sulfide: neurochemistry and neurobiology. Neurochem Int. 2008 Jan;52(1-2):155-65. Epub 2007 Jun 8. [PubMed:17629356]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Pyridoxal phosphate binding
- Specific Function
- Not Available
- Gene Name
- SDS
- Uniprot ID
- P20132
- Uniprot Name
- L-serine dehydratase/L-threonine deaminase
- Molecular Weight
- 34625.105 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Velayudhan J, Jones MA, Barrow PA, Kelly DJ: L-serine catabolism via an oxygen-labile L-serine dehydratase is essential for colonization of the avian gut by Campylobacter jejuni. Infect Immun. 2004 Jan;72(1):260-8. [PubMed:14688104]
- Snell K, Walker DG: Regulation of hepatic L-serine dehydratase and L-serine-pyruvate aminotransferase in the developing neonatal rat. Biochem J. 1974 Dec;144(3):519-31. [PubMed:4377655]
- Wong HC, Lessie TG: Hydroxy amino acid metabolism in Pseudomonas cepacia: role of L-serine deaminase in dissimilation of serine, glycine, and threonine. J Bacteriol. 1979 Oct;140(1):240-5. [PubMed:500557]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Threonine racemase activity
- Specific Function
- Catalyzes the synthesis of D-serine from L-serine. D-serine is a key coagonist with glutamate at NMDA receptors. Has dehydratase activity towards both L-serine and D-serine.
- Gene Name
- SRR
- Uniprot ID
- Q9GZT4
- Uniprot Name
- Serine racemase
- Molecular Weight
- 36565.905 Da
References
- Fujitani Y, Horiuchi T, Ito K, Sugimoto M: Serine racemases from barley, Hordeum vulgare L., and other plant species represent a distinct eukaryotic group: gene cloning and recombinant protein characterization. Phytochemistry. 2007 Jun;68(11):1530-6. Epub 2007 May 17. [PubMed:17499824]
- Ying-Luan Z, Zhao YL, Mori H: [Role of D-serine in the mammalian brain]. Brain Nerve. 2007 Jul;59(7):725-30. [PubMed:17663143]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serine c-palmitoyltransferase activity
- Specific Function
- Serine palmitoyltransferase (SPT). The heterodimer formed with LCB1/SPTLC1 constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the substrate ...
- Gene Name
- SPTLC2
- Uniprot ID
- O15270
- Uniprot Name
- Serine palmitoyltransferase 2
- Molecular Weight
- 62923.765 Da
References
- Yard BA, Carter LG, Johnson KA, Overton IM, Dorward M, Liu H, McMahon SA, Oke M, Puech D, Barton GJ, Naismith JH, Campopiano DJ: The structure of serine palmitoyltransferase; gateway to sphingolipid biosynthesis. J Mol Biol. 2007 Jul 27;370(5):870-86. Epub 2007 May 10. [PubMed:17559874]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serine c-palmitoyltransferase activity
- Specific Function
- Serine palmitoyltransferase (SPT). The heterodimer formed with SPTLC2 or SPTLC3 constitutes the catalytic core. The composition of the serine palmitoyltransferase (SPT) complex determines the subst...
- Gene Name
- SPTLC1
- Uniprot ID
- O15269
- Uniprot Name
- Serine palmitoyltransferase 1
- Molecular Weight
- 52743.41 Da
References
- Yard BA, Carter LG, Johnson KA, Overton IM, Dorward M, Liu H, McMahon SA, Oke M, Puech D, Barton GJ, Naismith JH, Campopiano DJ: The structure of serine palmitoyltransferase; gateway to sphingolipid biosynthesis. J Mol Biol. 2007 Jul 27;370(5):870-86. Epub 2007 May 10. [PubMed:17559874]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serine-trna ligase activity
- Specific Function
- Catalyzes the attachment of serine to tRNA(Ser). Is also probably able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into se...
- Gene Name
- SARS
- Uniprot ID
- P49591
- Uniprot Name
- Serine--tRNA ligase, cytoplasmic
- Molecular Weight
- 58776.785 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Zhang Y, Cui J, Zhang R, Wang Y, Hong M: A novel fibrinolytic serine protease from the polychaete Nereis (Neanthes) virens (Sars): purification and characterization. Biochimie. 2007 Jan;89(1):93-103. Epub 2006 Aug 22. [PubMed:16950556]
- Follis KE, York J, Nunberg JH: Serine-scanning mutagenesis studies of the C-terminal heptad repeats in the SARS coronavirus S glycoprotein highlight the important role of the short helical region. Virology. 2005 Oct 10;341(1):122-9. [PubMed:16081124]
- McClendon CL, Vaidehi N, Kam VW, Zhang D, Goddard WA 3rd: Fidelity of seryl-tRNA synthetase to binding of natural amino acids from HierDock first principles computations. Protein Eng Des Sel. 2006 May;19(5):195-203. Epub 2006 Mar 3. [PubMed:16517553]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Transaminase activity
- Specific Function
- Not Available
- Gene Name
- AGXT
- Uniprot ID
- P21549
- Uniprot Name
- Serine--pyruvate aminotransferase
- Molecular Weight
- 43009.535 Da
References
- Ikushiro H, Islam MM, Tojo H, Hayashi H: Molecular characterization of membrane-associated soluble serine palmitoyltransferases from Sphingobacterium multivorum and Bdellovibrio stolpii. J Bacteriol. 2007 Aug;189(15):5749-61. Epub 2007 Jun 8. [PubMed:17557831]
- Cowart LA, Hannun YA: Selective substrate supply in the regulation of yeast de novo sphingolipid synthesis. J Biol Chem. 2007 Apr 20;282(16):12330-40. Epub 2007 Feb 23. [PubMed:17322298]
- Son JH, Yoo HH, Kim DH: Activation of de novo synthetic pathway of ceramides is responsible for the initiation of hydrogen peroxide-induced apoptosis in HL-60 cells. J Toxicol Environ Health A. 2007 Aug;70(15-16):1310-8. [PubMed:17654249]
- Yard BA, Carter LG, Johnson KA, Overton IM, Dorward M, Liu H, McMahon SA, Oke M, Puech D, Barton GJ, Naismith JH, Campopiano DJ: The structure of serine palmitoyltransferase; gateway to sphingolipid biosynthesis. J Mol Biol. 2007 Jul 27;370(5):870-86. Epub 2007 May 10. [PubMed:17559874]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Transporter activity
- Specific Function
- Sodium-independent transporter that mediates the update of aromatic acid. Can function as a net efflux pathway for aromatic amino acids in the basosolateral epithelial cells (By similarity).
- Gene Name
- SLC16A10
- Uniprot ID
- Q8TF71
- Uniprot Name
- Monocarboxylate transporter 10
- Molecular Weight
- 55492.07 Da
References
- Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H: Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. J Biol Chem. 2001 May 18;276(20):17221-8. Epub 2001 Feb 20. [PubMed:11278508]
Drug created on June 13, 2005 07:24 / Updated on September 03, 2020 19:00
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates